Camille M. Le Gall, Jorieke Weiden, Loek J. Eggermont and Carl G. Figdor provide an overview of immunotherapeutics for cancer treatment that harness dendritic cells, their challenges in clinical use, and approaches employed to enhance their recruitment and activation to promote effective anti-tumour immunity.
This is a preview of subscription content, access via your institution
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Kantoff, P. W. et al. N. Engl. J. Med. 363, 2301–2303 (2010).
Bol, K. F., Schreibelt, G., Gerritsen, W. R., de Vries, I. J. M. & Figdor, C. G. Clin. Cancer Res. 22, 1897–1906 (2016).
Gross, S. et al. J. Clin. Ivestig. Insight 2, e91438 (2017).
Schreibelt, G. et al. Clin. Cancer Res. 22, 2155–2166 (2016).
Bonifaz, L. et al. J. Exp. Med. 196, 1627–1638 (2002).
Tacken, P. J. et al. Blood 118, 6836–6844 (2011).
Kranz, L. M. et al. Nature 534, 396–401 (2016).
Ali, O. A., Huebsch, N., Cao, L., Dranoff, G. & Mooney, D. J. Nat. Mater. 8, 151–158 (2009).
Shi, J., Kantoff, P. W., Wooster, R. & Farokhzad, O. C. Nat. Rev. Cancer 17, 20–37 (2017).
Dudziak, D. et al. Science 315, 107–112 (2007).
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Le Gall, C.M., Weiden, J., Eggermont, L.J. et al. Dendritic cells in cancer immunotherapy. Nature Mater 17, 474–475 (2018). https://doi.org/10.1038/s41563-018-0093-6
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41563-018-0093-6
